Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Author:
Affiliation:
1. Department of Hematology and Medical Oncology, Winship Cancer Institute; Emory University; Atlanta Georgia
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30740/fullpdf
Reference20 articles.
1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin.,2016
2. Improving outcomes for patients with diffuse large B-cell lymphoma;Flowers;CA Cancer J Clin.,2010
3. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte;Feugier;J Clin Oncol.,2005
4. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy;Maurer;J Clin Oncol.,2014
5. Cancer-specific mortality, #cure |fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era;Howlader;Cancer,2017
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP;Annals of Hematology;2024-06-20
2. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659);Oncotarget;2023-01-26
3. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon®) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma;Therapeutic Advances in Hematology;2023-01
4. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy;BMC Medicine;2022-10-25
5. Predictive value of baseline 18F‑FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B‑cell lymphoma receiving R‑CHOP chemotherapy;Oncology Letters;2020-12-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3